PubMed Health⌕ Search

Biomedical subjects

V Sobradillo

Publications and source records attributed to V Sobradillo.

43 records · Page 3Linked to original sources
PubMed1989

Q fever pneumonia: a review of 164 community-acquired cases in the Basque country.

One hundred and sixty four cases of Q fever pneumonia are reviewed. Coxiella burnetti is responsible for 18.8% of pneumonias acquired in the community in our region with an extremely high seasonal variation. 91% of the cases occur between January and June. 88.5% of the patients are less than 40 yrs of age and 77% are male. The most common clinical symptoms are high fever, cough, cephalalgia and myalgias. 46.5% of the patients have no respiratory symptoms although 34% of the cases report pleural pain. The radiological signs are nonspecific. With regard to laboratory data, it is often observed that the white blood cell count (WBC) is normal and the liver enzymes are abnormal (45%). Treatment with doxycycline reduces the fever more quickly than erythromycin.

Adult↗
PubMedDate not supplied

[Glycolytic metabolism during muscular excerise in chronic broncho-pulmonary disease without hypoxemia (author's transl)].

Maximum oxygen uptake (VO2 max) was measured in 11 chronic bronchitics without heart failure or hypoxemia at rest and during maximal work load, using a triangular type of excerise with increasing power (30 W/3 min). Glycolysis was studied in these patients during rectangular exercises lasting 10 minutes, in which power was increased by steps from an average value of 45 % to 72 and 94 % of VO2 max. The metabolic response of lactate in blood is similar to normal, during the limited performances of these patients.

Acid-Base Equilibrium↗
PubMedDate not supplied

[Double-blind clinical trial comparing 5 days of dirithromycin versus 7 days of diacetylmidecamycin in acute bronchitis and acute exacerbations of chronic bronchitis].

BACKGROUND: Dirythromycin has several pharmacokinetic characteristics (long half life and high tissue concentrations) which suggest the possibility of administering shorter treatments than those conventionally used. The aim of this study was to determine and compare the efficacy of a 5 day treatment with dirythromycin once a day, versus diacetylmidecamycin twice a day over 7 days in the treatment of patients with acute bronchitis and acute exacerbations of chronic bronchitis. METHODS: A parallel, multicentric, randomized, double blind clinical study was carried out in 8 Spanish hospitals. RESULTS: One hundred seventy-four patients were included in the study, with 87 (80 evaluable) being randomly assigned to receive dirythromycin (500 mg/day over 5 days) and 87 (83 evaluable) diacetylmidecamycin (600 mg, twice daily over 7 days). A favorable symptomatic response (cure or improvement) was observed in 72/80 of the first group (90%) and in 74/83 (89.2%) of the second group. No statistically significant differences were found in the efficacy and safety between the two treatment groups in either the evaluable patients or on intention to treat analysis. CONCLUSIONS: The results of this study suggest that the administration of dirythromycin, once a day over 5 days, is as safe and effective as diacetylmidecamycin, twice a day over 7 days, in the treatment of acute bronchitis and acute exacerbations of chronic bronchitis.

Acute Disease↗